PROK2 and diabetes mellitus: In summary, our data suggest that PK2 may participate in pathophysiological changes in DCM and that Met protects against diabetes-induced cardiac and remodeling, apoptosis, and dysfunction via activation of the PK2/PKR signaling, thereby regulating the AKT/GSK3β pathway.